196 322

Cited 0 times in

Living donor liver transplantation for Patients with beyond Milan hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김, 봉완-
dc.contributor.author배, 병구-
dc.contributor.author박, 용근-
dc.contributor.author원, 재환-
dc.contributor.author배, 재익-
dc.contributor.author허, 위광-
dc.contributor.author왕, 희정-
dc.contributor.author김, 명욱-
dc.description.abstractBackground: To find the patients who have a significant chance of cure with living donor liver transplantation (LDLT) among the patients suffering with beyond-Milan hepatocellular carcinoma (HCC), we retrospectively analyzed the tumor factors that could affect a good prognosis after LDLT for patients who suffer with beyond Milan HCC.

Methods: Between March 2005 and May 2007, 18 cases of LDLT for beyond Milan HCC were performed. None of the patients had preoperative radiological evidence of vascular invasion. Excluding the 3 cases of in-hospital mortality, we analyzed the survival, the disease-free survival and the prognostic factors for recurrence in 15 beyond Milan HCC patients. The mean follow-up period was 18.8 °± 8.8 months (range: 4-34 months).

Results: The two-year survival and disease-free survival rates after LDLT were 61.7% and 31.1%, respectively, in 15 beyond-Milan patients. Among them, 9 patients had recurrence of HCC during follow-up. The one-year survival rate after tumor recurrence was 55.5%. An alphafetoprotein (AFP) level < 400 ng/mL, Edmonson-Steiner histology grade I and II and the presence of graft rejection were analyzed as the good prognostic factors of disease-free survival after LDLT for beyond-Milan HCC (p < .05). The patients with negative preoperative positron emission tomography (PET) findings (n = 5) showed a better prognosis than the PET-positive patients (n = 10) with statistical significance (p = .05).

Conclusion: Allowing that HCC patients exceed the Milan criteria, we can find the potentially curable candidates for LDLT with using tumor biologic markers such as a serum AFP level < 400 ng/mL, negative PET uptake or low grade histology, as assessed by preoperative needle biopsy. Further investigation is needed to evaluate the relation between graft rejection and tumor recurrence after liver transplantation.
dc.titleLiving donor liver transplantation for Patients with beyond Milan hepatocellular carcinoma-
dc.title.alternativeMilan 기준을 넘는 간세포암에서 생체부분 간이식-
dc.subject.keyword생체부분 간이식-
dc.subject.keywordLiver transplantation-
dc.subject.keywordLiving Donors-
dc.subject.keywordMilan criteria-
dc.subject.keywordHepatocellular carcinoma-
dc.contributor.affiliatedAuthor김, 봉완-
dc.contributor.affiliatedAuthor배, 병구-
dc.contributor.affiliatedAuthor원, 제환-
dc.contributor.affiliatedAuthor배, 재익-
dc.contributor.affiliatedAuthor왕, 희정-
dc.contributor.affiliatedAuthor김, 명욱-
dc.type.localJournal Papers-
dc.citation.titleKorean journal of hepato-biliary-pancreatic surgery-
dc.identifier.bibliographicCitationKorean journal of hepato-biliary-pancreatic surgery, 12(3):162-167, 2008-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Radiology
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Files in This Item:
Korean journal of hepato-biliary-pancreatic surgery_12(3)_162-167.pdfDownload


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.